US Regulatory Reads, 2017: Inspection Tips, Experimentation, And Trump
Executive Summary
2017 was obviously dominated by news of political chaos coming out of the White House and, for the medtech industry, the year was bookended by its failure to win repeal of the medical device tax. But last year was an extremely fruitful period for new US FDA policies, pilot programs and other approaches intended to streamline the scrutiny of devices. Medtech Insight readers couldn't get enough of coverage and insights on US FDA inspections and compliance topics, which dominated our top 25 most popular US regulatory and policies stories for last year. Also making the list were pieces delving into the evolving, and very active, FDA under Scott Gottlieb, the agency's growing attention to digital health, and the impact of the Trump administration's deregulation emphasis.